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Abstract
Background: We investigated the risk for recurrent coronary events associated with insulin 
resistance in post-infarction patients from the Thrombogenic Factors and Recurrent Coronary 
Events (THROMBO) study.
Methods: The association between insulin resistance expressed by Homeostatic Model As-
sessment 2 for Insulin Resistance (HOMA2-IR) and the risk for recurrent coronary events 
was investigated in a cohort of 1,032 patients evaluated 2 months after myocardial infarction 
(MI) with a follow-up of 26 months. The endpoint for the study was recurrent coronary event 
defined as cardiac death, nonfatal MI, or unstable angina, whichever occurred first. We used 
time dependent survival analysis and Cox proportional hazards regression method to deter-
mine the association between HOMA2 categorized as high > 75th percentile and endpoints after 
adjustment for relevant clinical covariates and series of thrombogenic and dyslipogenic factors.
Results: High HOMA2-IR defined as in fourth quartile (≥ 2.4) was associated with increased 
risk for recurrent coronary events (HR 1.44; CI 1.03–2.01; p = 0.03) after adjustment for the 
clinical covariates: age, gender, diabetes, prior MI, pulmonary congestion, coronary artery 
bypass grafting and percutaneous transluminal coronary angioplasty. The highest risk of 
cardiac events was observed in non-obese patients (body mass index [BMI] ≤ 30 kg/m2) with 
high HOMA2-IR (HR 1.5; CI 1.02–2.22; p = 0.038). The plasma level of plasminogen activa-
tor inhibitor-1 was associated with higher risk for recurrent coronary events in patients with 
insulin resistance (HR 1.79; CI 1.05–3.03; p = 0.03, interaction p = 0.018).
Conclusions: In conclusion, insulin resistance predicts recurrence of coronary events in post-
-infarction population. HOMA2-IR is better than BMI in stratifying risk of recurrent coronary 
events. (Cardiol J 2015; 22, 5: 519–526)
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Introduction
Insulin resistance (IR) plays a role in pathogen-
esis of metabolic syndrome and diabetes mellitus 
[1]. For evaluation of IR in larger clinical studies, 
the Homeostatic Model Assessment (HOMA) in-
dex is commonly used [2]. Previously, IR measured 
in patients with coronary artery disease was associ-
ated with increased risk for coronary events and 
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mellitus [3, 4]. IR increased in-hospital mortality 
after acute coronary event [5, 6]. The aim of the 
current study was to evaluate whether HOMA adds 
predictive value in the population after myocardial 
infarction (MI) in long-term follow-up and in a large 
study group. Identifying patients with IR with re-
lation to their body mass index (BMI) may allow 
better risk stratification and initiation of aggressive 
risk factor modification after MI when lifestyle 
changes are more likely to be implemented [7].
Methods
Study population
This investigation is a sub-study of the Throm-
bogenic Factors and Recurrent Coronary Events 
(THROMBO) study. Detailed protocol and inclu-
sion criteria have been previously described [8]. 
THROMBO was a multicenter study examining the 
effect of lipids and thrombogenic factors on recur-
rent coronary events, nonfatal MI or cardiac death 
during a 26-month follow-up in patients with index 
MI. Between October 1 1994 and June 30 1997 
1,045 patients were enrolled and signed the con-
sent for participation in a 2-month post-infarction 
(baseline) visit. Glucose and insulin measurements 
were available for 1,032 of 1,045 patients (98.7%) 
and constituted the study population of this report.
Laboratory measurements
Fasting blood samples were drawn 2 months 
after index MI. Insulin was measured by radioim-
munoassay (coat-A-count diagnostic products). 
Plasma glucose was measured immediately after 
the blood was drawn by the enzymatic method us-
ing a glucose analyzer. HOMA2-IR was calculated 
using the online calculator downloaded from http://
www.dtu.ox.ac.uk. The BMI was calculated as 
body weight/height2 and expressed in kilograms 
per square meter [kg/m2]. The hemostatic factor 
analyses included measurement of factor VII, factor 
VIIa, fibrinogen, von Willebrand factor, and plas-
minogen activator inhibitor-1 (PAI-1). Addition-
ally, concentrations of apolipoprotein-B (apo-B), 
apolipoprotein A1, lipoprotein (A), cholesterol, 
high density lipoprotein and low density lipoprotein 
cholesterol, triglycerides and C-reactive protein 
(CRP) were measured.
The endpoint
The endpoint was defined as death due to 
coronary heart disease, recurrent nonfatal MI or 
unstable angina episode, whichever occurred first. 
Unstable angina definition included hospitalization 
during follow-up with an increase in either frequen-
cy or duration of angina symptoms, or development 
of new angina at rest — whichever occurred first 
with both requiring ischemic electrocardio-
gram (ECG) changes without enzyme elevation. 
A 2-member committee reviewed information on the 
endpoint events from appropriate medical records.
Statistical analysis
The effects of the HOMA2-IR by quartile on 
time to endpoint were examined graphically by the 
Kaplan-Meier method, and the log-rank statistic 
was used when comparing the difference in survival 
between each pair of curves. Nineteen patients who 
died of causes other than coronary heart disease 
were censored at the time of their death. The multi-
variate Cox proportional hazards regression analysis 
was performed with the Cox proportional regression 
hazards model (SAS PHREG computer program). 
The regression model was adjusted for factors that 
play a role in recurrent coronary events. To identify 
important clinical factors we included in the model 
previously pre-selected factors (age, sex, race, prior 
MI, prior stroke, history of diabetes mellitus, index 
infarct type by ECG [Q-wave vs. non–Q-wave], 
thrombolytic therapy, pulmonary congestion by 
chest roentgenogram, and ejection fraction during 
the index coronary event, and smoking status at 
enrollment) [8], and additionally we included factor 
identified by GRACE study (hypertension, coronary 
artery bypass grafting [CABG] and percutaneous 
transluminal coronary angioplasty [PTCA]) [9]. 
A significance level of p = 0.05 was used for entering 
a variable into the basic clinical model. The follow-
ing parameters enter clinical model: age, male, sex, 
diabetes mellitus, prior MI, pulmonary congestion 
on chest roentgenogram, PTCA and CABG. All 
probability values were 2-tailed, and p < 0.05 was 
considered significant.
Results
A total of 1,032 patients were analyzed. The 
clinical characteristics of the entire study popula-
tion and patients by HOMA2-IR status are pre-
sented in Table 1. Patients with high HOMA2-IR 
were more likely to be younger and less likely 
to be white, male, obese, male and with history 
of hypertension and diabetes. They were often 
treated with diuretics and angiotensin converting 
enzyme inhibitors. Patients categorized as having 
higher HOMA2-IR had higher BMI, fibrinogen, 
PAI-1, von Willebrand factor, apo-B, triglyceride 
and CRP.
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Table 1. Baseline characteristics according to Homeostatic Model Assessment 2 for Insulin Resistance 
(HOMA2-IR).
Characteristics All patients HOMA2 Q1-3 HOMA2 Q4
N 1,032 774 258
Age:
Mean 59 ± 12 59 ± 12 57 ± 12*
≥ 60 years 496 (48%) 383 (44%) 113 (49%)*
Male 774 (75%) 598 (77%) 181 (70%)*
White 770 (75%) 594 (77%) 176 (68%)*
BMI [kg/m2]:
Mean 28 ± 5.2 27 ± 4.7 30 ± 5.9**
BMI ≥ 30 285 (27%) 177 (23%) 108 (41%)*
History:
Prior myocardial infarction 192 (19%) 140 (18%) 52 (20%)
Hypertension 453 (44%) 319 (41%) 134 (52%)*
Diabetes mellitus 195 (19%) 90 (12%) 105 (41%)*
Stroke 29 (3%) 17 (2%) 12 (5%)
PTCA 122 (12%) 92 (12%) 30 (12%)
CABG 87 (8.5%) 59 (11%) 28 (8%)
Current cigarette smoker 246 (24%) 172 (22%) 74 (29%)
Type of infarction new Q wave 535 (52%) 390 (50%) 145 (56%)
Pulmonary congestion 181 (19%) 121 (16%) 60 (23%)*
Ejection fraction:
Mean 47 ± 12 47 ± 12 47 ± 12
< 0.30 113 (11%) 79 (10%) 34 (13%)
Thrombolytic therapy 355 (34%) 269 (35%) 86 (33%)
Medication at enrolment:
Acetylsalicylic acid 842 (82%) 630 (81%) 212 (82%)
ACE inhibitors 384 (37%) 272 (35%) 112 (43%)*
Beta-blockers 783 (76%) 586 (76%) 197 (76%)
Calcium channel blockers 210 (20%) 157 (20%) 53 (21%)
Diuretics 172 (17%) 110 (14%) 62 (24%)*
Statins 342 (33%) 262 (34%) 83 (32%)
Hemostatic factors:
D-Dimer [ng/mL] 521 ± 638 527 ± 697 509 ± 422 
Factor VII [%] 103 ± 43 103 ± 42 103 ± 45
Factor VIIa [ng/mL] 2.5 ± 1.7 2.5 ± 1.6 2.6 ± 1.8 
Fibrinogen [mg/dL] 352 ± 88 346 ± 82 370 ± 101*
Plasminogen activator inhibitor-1 [ng/mL] 28 ± 27 24 ± 22 39 ± 38**
Von Willebrand factor [U/dL] 149 ± 68 142 ± 64 168 ± 76**
Lipid and metabolic factors: 118 ± 25
Apolipoprotein A1 [mg/mL] 118 ± 25 121 ± 27 118 ± 24 
Apolipoprotein B [mg/mL] 123 ± 28 195 ± 43 126 ± 29*
Cholesterol [mg/mL] 197 ± 44 201 ± 43*
HDL-cholesterol [mg/mL] 39 ± 11 39 ± 11 37 ± 11*
LDL-cholesterol [mg/mL] 120 ± 38 120 ± 37 119 ± 39
Lipoprotein(a) [mg/mL] 24 ± 23 25 ± 23 22 ± 21
Triglyceride [mg/mL] 200 ± 117 187 ± 102 239 ± 145**
C-reactive protein [mg/L] 0.49 ± 0.7 0.42 ± 0.6* 0.7 ± 1.0*
Values are given as total number of patients and percentage or mean ± standard deviation; *p < 0.05 and **p < 0.0001 difference between 
patients with HOMA2-IR Q4 vs. Q1-3; ACE-inhibitors — angiotensin converting enzyme inhibitors; BMI — body mass index; CABG — coronary 
artery bypass graft surgery; PTCA — percutaneous transluminal coronary angioplasty
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The risk of recurrent cardiac events  
in patients with high HOMA2-IR
During a mean follow-up of 1.7 ± 0.89 years, 
the combined primary endpoint was met in 199 su - 
bjects including: 127 patients with unstable 
angina, 52 patients with MI and 20 patients with 
cardiac death.
In Kaplan-Meier survival analysis, patients 
with highest HOMA2-IR quartile had a significantly 
higher probability of recurrent coronary events 
(log-rank, p = 0.025) (Fig. 1).
In the multivariate models after adjustment 
for age, gender, diabetes, prior MI, pulmonary 
congestion on chest roentgenogram, PTCA and 
CABG patients with Q4: HOMA2-IR were at 
higher risk for recurrent coronary events (hazard 
ratio [HR] 1.44; confidence interval [CI] 1.03–2.01; 
p = 0.03) compared to patients in the lower 
3 quartiles (Table 2). When HOMA2-IR was ana-
lyzed separately for cardiac death, MI and unstable 
angina, only unstable angina was predicted with 
statistical significance (Table 2).
To examine whether the association between 
HOMA2-IR and clinical outcome was driven by 
a concurrent diagnosis of diabetes, we additionally 
analyzed interaction between diabetes status and 
HOMA2-IR that was not statistically different 
(interaction p = 0.07).
Figure 1. Cumulative probability of recurrent cardiac events in post-infarction patients by HOMA2-IR quartiles.
Table 2. The contribution of Homeostatic Model Assessment 2 for Insulin Resistance (HOMA2-IR) 
(Q4:Q1-3) to the risk of experiencing a recurrent cardiac event for patients in the top quartile (Q4 ≥ 2.4) 
compared to patients in the lower 3 quartiles.







Recurrent coronary event (cardiac death or 
myocardial infarction or unstable angina)
933; 76 1.44 1.03–2.01 0.030
Unstable angina 933; 123 1.51 1.02–2.25 0.039
Myocardial infarction 933; 48 1.19 0.63–2.26 0.579
Cardiac death 933; 23 1.34 0.55–3.27 0.508
The survival model includes adjustment for the following clinical variables: age, male sex, diabetes mellitus, prior myocardial infarction,  
pulmonary congestion on chest roentgenogram, percutaneous coronary intervention and coronary artery bypass grafting
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Clinical outcome of different metabolic 
groups as function of BMI and IR
We assessed whether BMI status affects re-
lationship between insulin sensitivity and risk for 
recurrent cardiac events. Kaplan-Meier survival 
analysis showed that non-obese patients with high 
HOMA2-IR had a significantly higher probability of 
recurrent coronary events (log-rank, p = 0.024). 
Non-obese and obese with low HOMA had a simi-
larly low risk (Fig. 2).
In the multivariate models after adjustment 
for relevant clinical covariates, non-obese insulin 
resistance patients remained at highest risk for 
recurrent coronary event (HR 1.50; CI 1.02–2.22; 
p = 0.038) (Table 3).
The contribution of thrombogenic and  
dyslipogenic factors for risk for recurrent 
coronary events
We evaluated if concomitant presence of high-
est risk quartile for evaluated thrombogenic and 
dyslipogenic factors and high HOMA2-IR will 
additionally incensed risk for recurrent coronary 
events. PAI-1 was associated with higher risk in 
patients with IR (HR 1.79; CI 1.05–3.03; p = 0.03, 
interaction p = 0.018) (Table 4).
Discussion
In primary risk stratification, IR predicts de-
velopment of cardiovascular disease independently 
Table 3. The contribution of Homeostatic Model Assessment 2 for Insulin Resistance (HOMA2-IR) 
(Q4:Q1-3) and obesity to the risk of experiencing a recurrent cardiac event. Reference group:  
non-obese with HOMA2-IR Q3-Q1, total: n = 933, number of events: 176.







Reference group: non-obese and obese  
with HOMA2-IR Q3-Q1
699; 118
Non-obese with HOMA2-IR Q4 136; 35 1.50 1.02–2.22 0.038
Obese with HOMA2-IR Q4 98; 23 1.34 0.84–2.16 0.214
The survival model includes adjustment for the following clinical variables: age, male, diabetes mellitus, prior myocardial infarction, pulmo-
nary congestion on chest roentgenogram, percutaneous coronary intervention and coronary artery bypass grafting
Figure 2. Cumulative probability of recurrent cardiac events in post-infarction patients with respect to body mass 
index and HOMA2-IR status. Gray line: non-obese with HOMA2-IR Q4, light blue: obese with HOMA2-IR Q4, blue: 
obese with HOMA2-IR Q3-Q1 and black: non-obese with HOMA2-IR Q3–Q1.
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of diabetes mellitus [10–12]. In acute hospital 
setting, IR is associated with increased mortality 
after acute coronary event [5, 6]. In our multi-
center prospective study, IR predicts recurrence 
of coronary events in post-infarction population. 
Analysis of specific components suggested that 
the main effect was related to prediction of unsta-
ble angina. Our study is consistent with previous 
observations, furthermore emphases significance 
of IR in development of acute cardiac events in 
population at high cardiovascular risk. Importantly, 
IR was associated with adverse prognosis after 
adjustment for important clinical factors including 
diabetes mellitus.
IR was measured 2 months after MI and 
therefore it is less likely to be associated with 
adrenergic surge as a part of the acute stress re-
sponses, but rather a representation of metabolic 
disturbances. It has been postulated that IR in the 
post-myocardial period may predispose patients to 
micro vascular, myocardial injury and larger infract 
size [13]. Emerging evidence supports direct pro 
atherogenic effect of IR [14, 15], as well as its direct 
adverse effect on myocardial contractility [16].
An adipocentric view of the metabolic dis-
turbances considers obesity the major clinical 
component for IR in peripheral metabolic tissues. 
However, the link between obesity and IR is com-
plex, as indicated by the fact that some extremely 
obese people are glucose tolerant, while others 
with a mild degree of obesity develop severe IR 
and diabetes. In our study, patients identified as 
non-obese with IR had a higher risk for recurrent 
coronary events. Although obesity is an independ-
ent predictor of clinical coronary disease in the 
Framingham study [17], the association becomes 
weaker after adjustment for hypertension, hyper-
cholesterolemia: features classically associated 
with obesity [18]. Noteworthy among people with 
established coronary artery disease is the fact 
that BMI is inversely associated with mortality, 
phenomenon known as “obesity paradox” in review 
[19]. It has been previously suggested that perhaps 
BMI is not a good parameter to explain the complex 
association of obesity and cardiovascular disease. 
Other parameters like visceral adiposity, body 
composition, waist circumference, body fat and free 
fat mass have a role in clinical practice [20]. Our 
study showed that HOMA2-IR is a better prognos-
tic factor than BMI in predicting risk for recurrent 
coronary events suggesting that intracellular lipid 
accumulation in ectopic tissue triggers pathological 
responses with subsequent impairment in insulin 
signaling in review [21].
In our population, patients with higher HOMA2- 
-IR index had higher level of von Willebrand factor, 
a marker of endothelial injury previously shown to 
be an independent risk factor for recurrent cardiac 
events in patients with diabetes [22]. Patients with 
higher HOMA2-IR had, similarly to patients with 
metabolic syndrome, higher level of apo-B, PAI-1 
and triglyceride, but presence of metabolic syn-
drome in our population did not predict risk for re-
current coronary events [23]. In our study, patients 
Table 4. The contribution of Homeostatic Model Assessment 2 for Insulin Resistance (HOMA2-IR) 
(Q4:Q1-3) and thrombogenic and dyslipogenic factors (Q4:Q1-3) to cardiac events.
HOMA2-IR Q4 HOMA2-IR Q1-3 Interaction  
P
Hazard ratio  
(95% CI)
P Hazard ratio  
(95% CI)
P
Plasminogen activator  
inhibitor-1 Q4
1.79 (1.05–3.03) 0.030 0.74 (0.46–1.26) 0.23 0.018
Apolipoprotein A1 Q1 2.5 (1.4–4.45) 0.001 1.23 (0.78–1.94) 0.37 0.055
Apolipoprotein B Q4 1.70 (0.94–3.11) 0.066 1.74 (1.18–2.57) 0.004 0.943
C-reactive protein Q4 1.76 (1.00–3.11) 0.050 1.33 (0.05–2.07) 0.2 0.435
HDL-cholesterol Q1 0.92 (0.51–1.66) 0.79 0.99(0.63–1.58) 0.99 0.843
LDL-cholesterol Q4 1.37 (0.75–2.5) 0.29 1.27 (0.85–1.92) 0.23 0.843
Triglycerides Q4 0.89 (0.51–0.54) 0.69 0.8 (0.5–1.28) 0.35 0.761
Factor VIIa Q4 1.54 (0.87–2.75) 0.137 0.85 (0.55–1.34) 0.50 0.1139
Von Willebrand factor Q4 1.24 (0.72–2.14) 0.423 0.96 (0.63–1.48) 0.88 0.466
Fibrinogen Q4 1.1 (0.73–1.67) 0.375 1.07 (0.62–1.85) 0.78 0.929
The survival model includes adjustment for the following clinical variables: age, male, diabetes mellitus, prior myocardial infarction,  
pulmonary congestion on chest roentgenogram, percutaneous coronary intervention and coronary artery bypass grafting
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with high HOMA2-IR and PAI-1 had increased risk 
for recurrent coronary events, but not patients with 
lower HOMA2-IR and high PAI-1 suggesting that 
presence of IR will modify risk associated with high 
PAI-1. The link between hypofibrinolysis and IR 
has been previously postulated [24, 25], but signifi-
cance of PAI-1 is not limited to thrombolysis [26]. 
Elevated plasma level of PAI-1 has been shown to 
predict risk for recurrent coronary events and first 
MI [27, 28], but its predictivity is attenuated after 
adjustment for IR [29].
Currently there are no guidelines for the treat-
ment of IR, especially in patients with cardiovascu-
lar risk [30]. It has been recognized that increased 
physical activity will improve insulin sensitivity 
[31]. For pharmacological intervention, metformin 
and insulin sensitizers for type 2 diabetes treat-
ment [32] or antihypertensive and lipid lowering 
drugs can also improve insulin sensitivity [33].
Conclusions
Our findings indicate that IR is a good clinical 
marker of increased risk and improving insulin sen-
sitivity may modify cardiovascular risk. HOMA2-IR 
is better than BMI in stratifying the risk of recur-
rent coronary events. Multilevel intervention to 
increase insulin sensitivity in people after MI may 
influence the clinical outcome.
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